🇺🇸 Busulfan/Cyclophosphamide in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 11
Most-reported reactions
- Cytomegalovirus Infection Reactivation — 2 reports (18.18%)
- Activated Partial Thromboplastin Time — 1 report (9.09%)
- Acute Graft Versus Host Disease — 1 report (9.09%)
- Acute Kidney Injury — 1 report (9.09%)
- Acute Lymphocytic Leukaemia Recurrent — 1 report (9.09%)
- Anaemia — 1 report (9.09%)
- Bk Virus Infection — 1 report (9.09%)
- Cardiac Septal Hypertrophy — 1 report (9.09%)
- Chronic Graft Versus Host Disease — 1 report (9.09%)
- Cystitis Haemorrhagic — 1 report (9.09%)
Other Oncology approved in United States
Frequently asked questions
Is Busulfan/Cyclophosphamide approved in United States?
Busulfan/Cyclophosphamide does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Busulfan/Cyclophosphamide in United States?
Tel-Aviv Sourasky Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.